



10/28/2004 13:36 9704680104

OPPEDAHL AND LARSON

PAGE 01/02

## PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail

Mail Stop ISSUE FEE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

or Fax (703) 746-4000

**INSTRUCTIONS:** This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

02121 7590 07/27/2004

OPPEDAHL AND LARSON LLP  
P O BOX 5068

DILLON, CO 80435-5068

10/21/2004 BSAYAS12 00000080 09780000

01 FC:2501 685.00 OP

## Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (703) 746-4000, on the date indicated below.

Lori South

(Depositor's name)

Lori South

(Signature)

October 20, 2004

(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/789,066	02/09/2001	C. Neil Kison	TDIG.P-001	9997

TITLE OF INVENTION: SKIN TREATMENT COMPOSITION AND METHODS OF USE

APPLN. TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	YES	\$665	\$0	\$665	10/27/2004
EXAMINER	ART UNIT	CLASS-SUBCLASS			
LAMM, MARINA	1616	424-401000			

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).  
 Change of correspondence address (or Change of Correspondence Address form PTO/SB/122 attached).  
 "Fee Address" indication (or "Fee Address" indication form PTO/SB/47; Rev 03-02 (or more recent) attached. Use of a Customer Number is required).

2. For printing on the patent front page, list (1) the names of up to 3 registered patent attorneys or agents OR, alternatively,  
(2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

Oppedahl & Larson LLC

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE

(B) RESIDENCE: (CITY AND STATE OR COUNTRY)

Please check the appropriate assignee category or categories (will not be printed on the patent);  individual  corporation or other private group entity  government

4a. The following fee(s) are enclosed:

4b. Payment of Fee(s):

Issue Fee  
 Publication Fee (No small entity discount permitted)  
 Advance Order - # of Copies \_\_\_\_\_

 A check in the amount of the fee(s) is enclosed. Payment by credit card. Form PTO-2038 is attached.

The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number 15-0610 (enclose an extra copy of this form).

5. Change in Entity Status (from status indicated above)

a. Applicant claims SMALL ENTITY status. See, e.g., 37 CFR 1.27(g)(2).

b. Applicant is not claiming SMALL ENTITY status. See, e.g., 37 CFR 1.27(g)(2).

The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.

(Authorized Signature)

(Date)

October 20, 2004

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO in process) an application. Confidentiality is neither required nor granted under 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time estimates vary based upon the complexity of the issues. As provided in the notice on the annual survey you receive time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMIT THIS FORM WITH FEE(S)

PTOL-85 (Rev. 07/04) Approved for use through 04/30/2007.

OMB 0651-0033 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

BEST AVAILABLE COPY

US patent Number 6,824,785

REQUEST FOR EXPEDITED ISSUANCE OF A CORRECTED PATENT

Pursuant to 37 CFR § 1.322(b) and MPEP § 1480.01, the undersigned requests a corrected patent.

Attached for convenient reference please find a copy of Form PTOL-85 received by USPTO on February 24, 2010. The Form PTOL-85 clearly shows the Attorney, Agent or firm to be:

Oppendahl & Larson LLP

Through the fault of the Patent and Trademark Office, the patent was issued with this on the front page:

(74) *Attorney, Agent, or Firm—Oppendahl & Larson LLP*

It will be appreciated that the prominence of the mistake (on the front page of the patent) is such that a certificate of correction would not be appropriate. It is thus requested that the Director issue a corrected patent in lieu thereof as a more appropriate form for certificate of correction, without expense to the patentee thereof. 37 CFR § 1.322(b).

Respectfully submitted,

/s/

Carl Oppendahl  
PTO Reg. No. 32746



US006824785B1

(12) **United States Patent**  
Kitson et al.

(10) **Patent No.:** US 6,824,785 B1  
(45) **Date of Patent:** Nov. 30, 2004

(54) **SKIN TREATMENT COMPOSITION AND METHODS OF USE**

(76) Inventors: **C. Neil Kitson**, 3414 W. King Edward Ave., Vancouver, BC (CA), V6S 1M3; **Jenifer L. Thewalt**, 3670 Trinity St., Vancouver, B.C. (CA), V5A 1S6

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 318 days.

(21) Appl. No.: **09/780,060**

(22) Filed: **Feb. 9, 2001**

**Related U.S. Application Data**

(60) Provisional application No. 60/181,374, filed on Feb. 9, 2000.

(51) **Int. Cl.** <sup>7</sup> ..... **A61K 7/00;** A61K 9/00; A61K 9/127

(52) **U.S. Cl.** ..... **424/401;** 424/400; 424/450; 514/937; 514/944

(58) **Field of Search** ..... 424/400, 401, 424/450; 514/937, 944

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

5,643,899 A 7/1997 Elias et al.  
5,720,963 A 2/1998 Smith  
5,916,578 A \* 6/1999 Kawada et al. .... 424/401

**FOREIGN PATENT DOCUMENTS**

WO WO-90/01323 A1 \* 2/1990

**OTHER PUBLICATIONS**

"Concise Encyclopedia of Chemistry", p. 599, 1994.\*  
Abraham, et al.; "Investigation of Membrane Structure and Dynamics by Deuterium NMR: Application to the Stratum Corneum" in Mechanisms of Transdermal Drug Delivery; Potts and Guy, eds.; 1997; pp163-198.  
Wertz, et al.; "Covalently Bound Lipids of Human Stratum Corneum"; J. Invest Dermatol 92:109-111, 1989; pp109-111.

Imokawa, et al.; Importance of intercellular lipids in water-retention properties of the stratum corneum: induction and recovery study of surfactant dry skin; Arch Dermatol Res (1989) 281:45-51.

Abraham, et al.; "Fusion Patterns of Liposomes Formed from Stratum Corneum Lipids"; J. Invest Dermatol 90:259-262; 1988.

Pilgram, et al.; "Electron Diffraction Provides New Information on Human Stratum Corneum Lipid Organization Studied in Relation Depth and Temperature"; J. Invest Dermatol 113:403-409, 1999.  
Kitson, et al.; "A Model Membrane Approach to the Epidermal Permeability Barrier"; American Chemical Society, 1994; pp 6707-6715.

Imokawa, et al.; "Selective Recovery of Deranged Water-Holding Properties by Stratum Corneum Lipids"; The Society for Investigative Dermatology, Inc. 1986; pp758-761.  
Wertz, et al.; "Essential Fatty Acids and Epidermal Integrity"; Arch Dermatol—vol. 123, Oct. 1987; pp1381-1384.  
Bouwstra, et al.; "A Model Membrane Approach to the Epidermal Permeability Barrier: An X-ray Diffraction Study"; Biochemistry 1997; 7717-7725.

Imokawa; "Stratum Corneum Lipids Serve as a Bound-Water Modulator"; The Society for Investigative Dermatology, Inc. 1991; pp 845-851.

Man, et al.; Exogenous Lipids Influence Permeability Barrier Recovery in Acetone-Treated Murine Skin; Arch Dermatol—vol. 129, Jun. 1993; pp 728-738.

Thewalt, et al.; Models of Stratum Corneum Intercellular Membranes: The Sphingolipid Headgroup is a Determinant of Phase Behavior in Mixed Lipid Dispersions; Biochemical and Biophysical Research Communications, vol. 188, No. 3, 1992; pp 1247-1252.

Proksch, et al.; "Barrier Function Regulates Epidermal DNA Synthesis"; The Journal of Clinical Investigation, Inc., vol. 87, May 1991, 1668-1673.

Schuerer, et al.; "The Biochemistry and Function of Stratum Corneum Lipids"; Advances in Lipid Research, vol. 24, pp 27-56; 1991.

Elias, et al.; "Structural and Lipid Biochemical Correlates of the Epidermal Permeability Barrier"; Advances in Lipid Research, vol. 24, pp. 1-26, 1991.

Abraham, et al.; "Interaction between corneocytes and stratum corneum lipid liposomes *in vitro*"; Elsevier Science Publishers B.V. (Biomedical Division) 1990, pp 119-125.

Abraham, et al.; "Effect of epidermal acylglycosylceramides and acylceramides on the morphology of liposomes prepared from stratum corneum lipids"; Biochimica et Biophysica Acta 939 (1988) 403-408.

Ansari, et al.; "Fatty Acid Composition of the Living Layer and Stratum Corneum Lipids of Human Sole Skin Epidermis"; Lipids, vol. 5, No. 10, pp 838-845, 1970.

Wertz, et al.; "Hydroxyacid Derivatives in Human Epidermis"; Lipids, vol. 23, No. 5 (1988).

Cullis, et al.; "The Bilayer Stabilizing Role of Sphingomyelin in the Presence of Cholesterol"; Biochimica et Biophysica Acta, 597 (1980) 533-542.

Monash, et al.; "Location and Re-Formation of the Epithelial Barrier to Water Vapor"; A.M.A. Archives of Dermatology; vol. 73, Dec. 1958.

\* cited by examiner

**Primary Examiner—Gary Kunz**

**Assistant Examiner—Marina Lamm**

(74) **Attorney, Agent, or Firm—Oppendahl & Larson LLP**

(57)

**ABSTRACT**

A composition which when topically applied to the skin of a mammal reduces trans-epidermal water-loss and provides an improved epidermal barrier contains an aqueous dispersion of at least two lipids, preferably at least three lipids, in a non-crystalline phase lamellar array, preferably bilayer membranes in the form of liposomes. These lipids adopt a crystalline lamellar phase upon application to mammalian skin which resist washing with mild detergents and water. The composition can be formulated as a pharmaceutical preparation, and can be used in a method of recovering or otherwise improving a mammalian skin permeability barrier by administering the composition to the skin or hair and allowing the composition to dry. The dried composition adopts a crystalline lamellar phase after said administering to the skin. The composition thus provides a permeability barrier in cases where the natural barrier has been depleted, damaged or requires improvement. This barrier resists removal by detergent, solvent, or mechanical means over an extended period of time.